Glenmark launches empagliflozin combinations for Indian cardiometabolic market

** Glenmark Pharmaceuticals (BSE: GLENMARK) has launched Empagliflozin under the brand names Glempa, Glempa-L, and Glempa-M, targeting the growing cardiometabolic market in India. This move expands Glenmark's portfolio, providing new treatment options for Type 2 Diabetes Mellitus (T2DM) patients. Studies have shown that Empagliflozin offers benefits beyond glycemic control, including weight loss and reduced cardiovascular risks. The newly launched drugs aim to improve glycemic control and reduce cardiovascular outcomes in T2DM patients with existing CV risk. According to IQVIA sales data (MAT January 2025), the Indian market for Empagliflozin and its combinations is valued at ₹642 Crores.